2. Academic Validation
  3. Meeting report: 31st International Conference on Antiviral Research

Meeting report: 31st International Conference on Antiviral Research

  • Antiviral Res. 2018 Oct;158:88-102. doi: 10.1016/j.antiviral.2018.08.002.
Mike Bray 1,  Graciela Andrei 2,  Ester Ballana 3,  Kara Carter 4,  David Durantel 5,  Brian Gentry 6,  Zlatko Janeba 7,  Jennifer Moffat 8,  Clasien J Oomen 9,  Bart Tarbet 10,  Eva Riveira-Muñoz 11,  José A Esté 12,  International Society for Antiviral Research
Affiliations

Affiliations

  • 1 Chevy Chase, MD, USA.
  • 2 KU Leuven, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
  • 3 AIDS Research Institute - Irsicaixa, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.
  • 4 Evotec, Sudbury, MA, USA.
  • 5 Cancer Research Centre of Lyon (CRCL), INSERM, U1052, UMR_5286 CNRS/University of Lyon, Lyon, France.
  • 6 Drake University College of Pharmacy and Health Sciences, Des Moines, IA, USA.
  • 7 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nam. 2, CZ-16610 Prague 6, Czech Republic.
  • 8 SUNY Upstate Medical University, Syracuse, NY, USA.
  • 9 Virology Division, Dept. of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
  • 10 Institute for Antiviral Research, Utah State University, Logan, UT, USA.
  • 11 AIDS Research Institute - Irsicaixa, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain. Electronic address: [email protected].
  • 12 AIDS Research Institute - Irsicaixa, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain. Electronic address: [email protected].
PMID: 30086336 DOI: 10.1016/j.antiviral.2018.08.002
Abstract

The 31st International Conference on Antiviral Research (ICAR) was held in Porto, Portugal from June 11-15, 2018. In this report, volunteer rapporteurs provide their summaries of scientific presentations, hoping to effectively convey the speakers' goals and the results and conclusions of their talks. This report provides an overview of the invited keynote and award lectures and highlights of short oral presentations, from the perspective of experts in Antiviral research. Of note, a session on human cytomegalovirus included an update on the introduction to the clinic of letermovir for the prevention of CMV Infection and disease. The 31st ICAR successfully promoted new discoveries in Antiviral research and drug development. The 32nd ICAR will be held in Baltimore, Maryland, USA, May 6-10, 2019.

Figures
Products